Sign in Subscribe
Drugs

Cancer Therapy Advances: Targeting Angiogenesis with New Approaches

Strategic Insights

— 1 min read

Researchers in the United States and Japan have reported significant advances in cancer therapy by targeting angiogenesis, a crucial process in tumor growth and metastasis. Their studies demonstrate the effectiveness of new approaches in inhibiting vascular endothelial growth factor (VEGF) and its receptors, as well as other signaling pathways involved in tumor growth and angiogenesis.

Key Takeaways:

  • Study 1: Cetuximab (C225; Erbitux) has been shown to arrest hypoxia-inducible factor-1 alpha (HIF-1 alpha) expression, leading to transcriptional inhibition of VEGF expression in A431 epidermoid carcinoma cells. This study was conducted by researchers at the M.D. Anderson Cancer Center and published in Oncogene (2005;24(27):4433-4441).
  • Study 2: ZD6474, a novel inhibitor of VEGF receptor-2 (KDR) tyrosine kinase, demonstrated significant antitumor activity in gefitinib-sensitive and resistant lung adenocarcinoma cell lines. The study was conducted by scientists at the National Cancer Center in Japan and published in Cancer Science (2004;95(12):984-989).
  • Study 3: SU5416, a multi-targeted kinase inhibitor, efficiently blocked Kit-induced VEGF expression in small cell lung cancer (SCLC) xenografts. The study was conducted by researchers at the Richmond Veterans Affairs Medical Center in the United States and published in Lung Cancer (2004;46(3):283-291).
  • These studies highlight the potential of targeting angiogenesis as a therapeutic strategy in cancer treatment, particularly in combination with existing treatments.
  • The research suggests that new approaches such as cetuximab, ZD6474, and SU5416 could be effective in treating various malignancies, including lung cancer.

Statistics:

  • Cetuximab reduced HIF-1 alpha levels by 50% in A431 cells under normoxic and hypoxic culture conditions.
  • ZD6474 inhibited EGFR phosphorylation by 30-50% in PC-9 cells and 20-30% in PC-9/ZD cells.
  • SU5416 inhibited growth by at least 70% in H526 xenografts and 40% in H209 xenografts.
  • Microvessel density in SU5416-treated xenografts decreased by approximately 50%.

Sources:

  • Luwor, R. B., et al. (2005). "The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression." Oncogene, 24(27), 4433-4441.
  • Taguchi, F., et al. (2004). "Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (Iressa)-sensitive and resistant xenograft models." Cancer Sci, 95(12), 984-989.
  • Litz, J., et al. (2004). "The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression." Lung Cancer, 46(3), 283-291.

Read more